Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech
Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018 Capital Markets and Public M&A

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge advises Xamera Group on the acquisition of the Finnish company Integrify

 Xamera Group, partly owned by Helix Kapital, has acquired all the shares in the Finnish company Integrify, a leading Finnish provider of technology-focused and hire-purchase-based skills provision to the industrial, defence and tech sectors.
August 20, 2026

Vinge advises Advania on the acquisition of Cortex Consult A/S

 Vinge has advised Advania on the acquisition of Cortex Consult A/S, a Danish IT services company with more than 25 years of experience in managed IT services, cloud solutions and cybersecurity for customers across a range of industries.
August 18, 2026

Vinge advises Radonova Laboratories on the acquisition of the Norwegian company Skandinavisk Radoninvest

 Radonova Laboratories, a subsidiary of the Lagercrantz Group, has acquired all the shares in the Norwegian company Skandinavisk Radoninvest. Both companies operate in the field of radon measurement.
August 14, 2026